Zuurstoftoediening met hoge nasale flow bij covid-19

Translated title of the contribution: High flow nasal oxygen in patients with COVID-19

Judith Elshof*, Evert Jan Wils, Leo M.A. Heunks, Peter Dieperink, Marieke L. Duiverman

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

Abstract

High flow nasal oxygen (HFNO) is proven to be effective in non-COVID-19 hypoxemic respiratory failure. In the beginning of the COVID-19 pandemic, HFNO was quickly introduced into daily clinical practice, although the evidence of its effectiveness in COVID-19 was limited. Randomized controlled trials suggest that HFNO has no effect on survival. However, HFNO may lead to less intubations in comparison with conventional oxygen therapy. The evidence of HFNO use in patients with do-not-intubate orders remains very limited. However, in these patients, improvement in comfort could be an important argument to start treatment with HFNO. Additional research is needed to make an evidence based consideration about the clinical use of HFNO in COVID-19 care.

Translated title of the contributionHigh flow nasal oxygen in patients with COVID-19
Original languageDutch
JournalNederlands Tijdschrift voor Geneeskunde
Volume166
Publication statusPublished - 26 Sep 2022

Fingerprint

Dive into the research topics of 'High flow nasal oxygen in patients with COVID-19'. Together they form a unique fingerprint.

Cite this